RKIP acts as a tumour suppressor in primary Acute Myeloid Leukaemia (AML) its loss increases the invasion and migration potential of a series of AML cell lines and promotes, in vivo, the formation of extramedullary metastases [64]. Here, PEBP1 is linked to acute myeloid leukemia.